CY1121459T1 - Συνθεση ενωσεων τιακουμικινης - Google Patents
Συνθεση ενωσεων τιακουμικινηςInfo
- Publication number
- CY1121459T1 CY1121459T1 CY20181101410T CY181101410T CY1121459T1 CY 1121459 T1 CY1121459 T1 CY 1121459T1 CY 20181101410 T CY20181101410 T CY 20181101410T CY 181101410 T CY181101410 T CY 181101410T CY 1121459 T1 CY1121459 T1 CY 1121459T1
- Authority
- CY
- Cyprus
- Prior art keywords
- composition
- tiacumicine
- compounds
- sodium
- tiacumycin
- Prior art date
Links
- 239000000203 mixture Substances 0.000 title abstract 5
- 150000001875 compounds Chemical class 0.000 title abstract 3
- 229920002907 Guar gum Polymers 0.000 abstract 2
- 229920000168 Microcrystalline cellulose Polymers 0.000 abstract 2
- DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 abstract 2
- 239000004480 active ingredient Substances 0.000 abstract 2
- 239000001768 carboxy methyl cellulose Substances 0.000 abstract 2
- 235000010418 carrageenan Nutrition 0.000 abstract 2
- 239000000679 carrageenan Substances 0.000 abstract 2
- 229920001525 carrageenan Polymers 0.000 abstract 2
- 229940113118 carrageenan Drugs 0.000 abstract 2
- 239000001913 cellulose Substances 0.000 abstract 2
- 229920002678 cellulose Polymers 0.000 abstract 2
- 235000010980 cellulose Nutrition 0.000 abstract 2
- 239000000665 guar gum Substances 0.000 abstract 2
- 235000010417 guar gum Nutrition 0.000 abstract 2
- 229960002154 guar gum Drugs 0.000 abstract 2
- 239000008108 microcrystalline cellulose Substances 0.000 abstract 2
- 229940016286 microcrystalline cellulose Drugs 0.000 abstract 2
- 235000019813 microcrystalline cellulose Nutrition 0.000 abstract 2
- 239000000546 pharmaceutical excipient Substances 0.000 abstract 2
- 235000019812 sodium carboxymethyl cellulose Nutrition 0.000 abstract 2
- 229920001027 sodium carboxymethylcellulose Polymers 0.000 abstract 2
- 239000012453 solvate Substances 0.000 abstract 2
- 239000000230 xanthan gum Substances 0.000 abstract 2
- 235000010493 xanthan gum Nutrition 0.000 abstract 2
- 229920001285 xanthan gum Polymers 0.000 abstract 2
- 229940082509 xanthan gum Drugs 0.000 abstract 2
- UHVMMEOXYDMDKI-JKYCWFKZSA-L zinc;1-(5-cyanopyridin-2-yl)-3-[(1s,2s)-2-(6-fluoro-2-hydroxy-3-propanoylphenyl)cyclopropyl]urea;diacetate Chemical compound [Zn+2].CC([O-])=O.CC([O-])=O.CCC(=O)C1=CC=C(F)C([C@H]2[C@H](C2)NC(=O)NC=2N=CC(=CC=2)C#N)=C1O UHVMMEOXYDMDKI-JKYCWFKZSA-L 0.000 abstract 2
- IXPNQXFRVYWDDI-UHFFFAOYSA-N 1-methyl-2,4-dioxo-1,3-diazinane-5-carboximidamide Chemical compound CN1CC(C(N)=N)C(=O)NC1=O IXPNQXFRVYWDDI-UHFFFAOYSA-N 0.000 abstract 1
- FHVDTGUDJYJELY-UHFFFAOYSA-N 6-{[2-carboxy-4,5-dihydroxy-6-(phosphanyloxy)oxan-3-yl]oxy}-4,5-dihydroxy-3-phosphanyloxane-2-carboxylic acid Chemical compound O1C(C(O)=O)C(P)C(O)C(O)C1OC1C(C(O)=O)OC(OP)C(O)C1O FHVDTGUDJYJELY-UHFFFAOYSA-N 0.000 abstract 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 abstract 1
- 229940072056 alginate Drugs 0.000 abstract 1
- 235000010443 alginic acid Nutrition 0.000 abstract 1
- 229920000615 alginic acid Polymers 0.000 abstract 1
- 239000011734 sodium Substances 0.000 abstract 1
- 229910052708 sodium Inorganic materials 0.000 abstract 1
- 235000010413 sodium alginate Nutrition 0.000 abstract 1
- 239000000661 sodium alginate Substances 0.000 abstract 1
- 229940005550 sodium alginate Drugs 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
- A61K47/38—Cellulose; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
- A61K31/7034—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7048—Compounds having saccharide radicals and heterocyclic rings having oxygen as a ring hetero atom, e.g. leucoglucosan, hesperidin, erythromycin, nystatin, digitoxin or digoxin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0087—Galenical forms not covered by A61K9/02 - A61K9/7023
- A61K9/0095—Drinks; Beverages; Syrups; Compositions for reconstitution thereof, e.g. powders or tablets to be dispersed in a glass of water; Veterinary drenches
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1629—Organic macromolecular compounds
- A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Molecular Biology (AREA)
- Engineering & Computer Science (AREA)
- Inorganic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Biochemistry (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP13075002 | 2013-01-15 | ||
| EP14701907.9A EP2945613B1 (en) | 2013-01-15 | 2014-01-14 | Composition of tiacumicin compounds |
| PCT/EP2014/000091 WO2014111254A1 (en) | 2013-01-15 | 2014-01-14 | Composition of tiacumicin compounds |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CY1121459T1 true CY1121459T1 (el) | 2020-05-29 |
Family
ID=47563169
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CY20181101410T CY1121459T1 (el) | 2013-01-15 | 2018-12-28 | Συνθεση ενωσεων τιακουμικινης |
Country Status (28)
| Country | Link |
|---|---|
| US (1) | US9808530B2 (enExample) |
| EP (1) | EP2945613B1 (enExample) |
| JP (1) | JP6338598B2 (enExample) |
| KR (1) | KR102181474B1 (enExample) |
| CN (1) | CN105120840B (enExample) |
| AR (1) | AR094495A1 (enExample) |
| AU (1) | AU2014207083B2 (enExample) |
| CA (1) | CA2904808A1 (enExample) |
| CY (1) | CY1121459T1 (enExample) |
| DK (1) | DK2945613T3 (enExample) |
| EA (1) | EA030049B1 (enExample) |
| ES (1) | ES2705238T3 (enExample) |
| GE (1) | GEP201706769B (enExample) |
| HR (1) | HRP20182110T1 (enExample) |
| HU (1) | HUE041421T2 (enExample) |
| IL (1) | IL239899A0 (enExample) |
| JO (1) | JO3464B1 (enExample) |
| LT (1) | LT2945613T (enExample) |
| MD (1) | MD4588C1 (enExample) |
| NZ (1) | NZ710875A (enExample) |
| PL (1) | PL2945613T3 (enExample) |
| PT (1) | PT2945613T (enExample) |
| RS (1) | RS58119B1 (enExample) |
| SI (1) | SI2945613T1 (enExample) |
| TW (1) | TWI646962B (enExample) |
| UA (1) | UA117004C2 (enExample) |
| WO (1) | WO2014111254A1 (enExample) |
| ZA (1) | ZA201505048B (enExample) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2015169451A1 (en) | 2014-05-09 | 2015-11-12 | Astellas Pharma Europe Ltd | Treatment regimen tiacumicin compound |
| CN110037992B (zh) * | 2019-05-28 | 2021-05-28 | 杭州华东医药集团新药研究院有限公司 | 一种稳定的非达霉素组合物 |
| CN116715678B (zh) * | 2023-06-12 | 2025-09-30 | 中国科学院成都生物研究所 | 一种吲哚糖碳苷类大环化合物及其制备方法与应用 |
Family Cites Families (35)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3000792A (en) | 1957-05-21 | 1961-09-19 | Merck & Co Inc | Antibiotic adsorption process |
| GB1458512A (en) | 1973-11-22 | 1976-12-15 | Lepetit Spa | Antibiotic substance |
| US4632902A (en) | 1981-08-20 | 1986-12-30 | Becton, Dickinson And Company | Method for detecting biological activity in a body fluid |
| US4918174A (en) | 1986-09-26 | 1990-04-17 | Abbott Laboratories | Tiacumicin compounds |
| CA2384529C (en) | 1991-03-04 | 2007-01-02 | Bayer Corporation | Automated analyzer |
| US5583115A (en) | 1995-05-09 | 1996-12-10 | Abbott Laboratories | Dialkyltiacumicin compounds |
| US5767096A (en) | 1996-07-12 | 1998-06-16 | Abbott Laboratories | Bromotiacumicin compounds |
| ATE267197T1 (de) | 1996-11-18 | 2004-06-15 | Biotechnolog Forschung Gmbh | Epothilon d, dessen herstellung und dessen verwendung als cytostatisches mittel bzw. als pflanzenschutzmittel |
| JP2000072760A (ja) | 1998-06-19 | 2000-03-07 | Ajinomoto Co Inc | 新規シストチアゾール類縁体 |
| JP2000053514A (ja) | 1998-08-06 | 2000-02-22 | Aquas Corp | レジオネラ属細菌が生産する殺菌性物質、これを用いた殺菌剤、水処理剤、スライム抑制剤、及びこれらの製造方法 |
| JP2000239266A (ja) | 1999-02-17 | 2000-09-05 | Ajinomoto Co Inc | 新規ポリエン系抗生物質 |
| WO2001083800A2 (en) | 2000-04-28 | 2001-11-08 | Kosan Biosciences, Inc. | Heterologous production of polyketides |
| WO2002032427A1 (en) | 2000-10-20 | 2002-04-25 | Galephar M/F | Stable oral formulation containing benzimidazole derivative |
| US20030099699A1 (en) | 2001-11-13 | 2003-05-29 | Hanshew Dwight D. | Storage stable thyroxine active drug formulations and methods for their production |
| US7507564B2 (en) | 2002-07-29 | 2009-03-24 | Optimer Pharmaceuticals, Inc. | Tiacumicin production |
| WO2006085838A1 (en) | 2005-01-31 | 2006-08-17 | Optimer Pharmaceuticals, Inc. | 18-membered macrocycles and analogs thereof |
| US20070105791A1 (en) | 2002-07-29 | 2007-05-10 | Optimer Pharmaceuticals, Inc. | Method of treating clostridium difficile-associated diarrhea |
| US20080206161A1 (en) * | 2002-10-25 | 2008-08-28 | Dov Tamarkin | Quiescent foamable compositions, steroids, kits and uses thereof |
| US9211259B2 (en) | 2002-11-29 | 2015-12-15 | Foamix Pharmaceuticals Ltd. | Antibiotic kit and composition and uses thereof |
| US20040224020A1 (en) | 2002-12-18 | 2004-11-11 | Schoenhard Grant L. | Oral dosage forms with therapeutically active agents in controlled release cores and immediate release gelatin capsule coats |
| WO2005009474A1 (ja) | 2003-07-24 | 2005-02-03 | Shionogi & Co., Ltd. | 難水溶性薬物を含むドライシロップ剤 |
| JP3881640B2 (ja) | 2003-08-08 | 2007-02-14 | 塩野義製薬株式会社 | ロラタジンを含むドライシロップ剤 |
| ES2395404T3 (es) | 2004-05-14 | 2013-02-12 | Optimer Pharmaceuticals, Inc. | Tratamiento de las enfermedades asociadas al uso de antibióticos |
| US7906489B2 (en) | 2004-05-14 | 2011-03-15 | Optimer Pharmaceuticals, Inc. | 18-membered macrocycles and analogs thereof |
| US8586551B2 (en) | 2005-01-31 | 2013-11-19 | Optimer Pharmaceuticals, Inc. | 18-membered macrocycles and analogs thereof |
| US7378508B2 (en) | 2007-01-22 | 2008-05-27 | Optimer Pharmaceuticals, Inc. | Polymorphic crystalline forms of tiacumicin B |
| WO2006114709A1 (en) * | 2005-04-25 | 2006-11-02 | Aurobindo Pharma Limited | Pharmaceutical compositions of antiretrovirals |
| CA2626698C (en) | 2005-10-21 | 2015-12-01 | Optimer Pharmaceuticals, Inc. | Method of treating clostridium difficile-associated diarrhea |
| US20080176927A1 (en) * | 2007-01-19 | 2008-07-24 | Optimer Pharmaceuticals, Inc. | Compositions of stable tiacumicins |
| ZA200905337B (en) | 2007-01-22 | 2010-10-27 | Optimer Pharmaceuticals Inc | Macrocyclic polymorphs, compositions comprising such polymorphs, and methods of use and manufacture thereof |
| US8999395B2 (en) * | 2007-02-09 | 2015-04-07 | Ceva Sante Animale | Pharmaceutical compositions for oral administration in the form of stabilised aqueous suspensions |
| TWI523654B (zh) | 2007-11-27 | 2016-03-01 | 默沙東藥廠 | 抗生素巨環化合物以及其製造及使用之方法 |
| JP5608880B2 (ja) * | 2010-02-09 | 2014-10-22 | 林兼産業株式会社 | 嚥下困難者用高栄養ゼリー食品 |
| CN102030791B (zh) | 2010-10-28 | 2013-01-23 | 中国科学院南海海洋研究所 | 四种台勾霉素类化合物及其制备方法和在制备抗菌药物中的应用 |
| CN102115757B (zh) | 2010-12-14 | 2015-10-28 | 中国科学院南海海洋研究所 | 台勾霉素的生物合成基因簇及其应用 |
-
2014
- 2014-01-13 JO JOP/2014/0006A patent/JO3464B1/ar active
- 2014-01-14 KR KR1020157021986A patent/KR102181474B1/ko not_active Expired - Fee Related
- 2014-01-14 CN CN201480015374.9A patent/CN105120840B/zh not_active Expired - Fee Related
- 2014-01-14 SI SI201430997T patent/SI2945613T1/sl unknown
- 2014-01-14 RS RS20181542A patent/RS58119B1/sr unknown
- 2014-01-14 US US14/766,904 patent/US9808530B2/en active Active
- 2014-01-14 CA CA2904808A patent/CA2904808A1/en not_active Abandoned
- 2014-01-14 MD MDA20150070A patent/MD4588C1/ro active IP Right Grant
- 2014-01-14 PT PT14701907T patent/PT2945613T/pt unknown
- 2014-01-14 HR HRP20182110TT patent/HRP20182110T1/hr unknown
- 2014-01-14 JP JP2015553034A patent/JP6338598B2/ja active Active
- 2014-01-14 NZ NZ71087514A patent/NZ710875A/en not_active IP Right Cessation
- 2014-01-14 UA UAA201506802A patent/UA117004C2/uk unknown
- 2014-01-14 HU HUE14701907A patent/HUE041421T2/hu unknown
- 2014-01-14 EP EP14701907.9A patent/EP2945613B1/en active Active
- 2014-01-14 DK DK14701907.9T patent/DK2945613T3/en active
- 2014-01-14 PL PL14701907T patent/PL2945613T3/pl unknown
- 2014-01-14 GE GEAP201413898A patent/GEP201706769B/en unknown
- 2014-01-14 EA EA201591226A patent/EA030049B1/ru unknown
- 2014-01-14 WO PCT/EP2014/000091 patent/WO2014111254A1/en not_active Ceased
- 2014-01-14 AU AU2014207083A patent/AU2014207083B2/en not_active Ceased
- 2014-01-14 ES ES14701907T patent/ES2705238T3/es active Active
- 2014-01-14 LT LTEP14701907.9T patent/LT2945613T/lt unknown
- 2014-01-15 TW TW103101528A patent/TWI646962B/zh not_active IP Right Cessation
- 2014-01-15 AR ARP140100152A patent/AR094495A1/es unknown
-
2015
- 2015-07-12 IL IL239899A patent/IL239899A0/en active IP Right Grant
- 2015-07-14 ZA ZA2015/05048A patent/ZA201505048B/en unknown
-
2018
- 2018-12-28 CY CY20181101410T patent/CY1121459T1/el unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CY1123953T1 (el) | Καθυστερημενης απελευθερωσης συνθεσεις λινακλοτιδης | |
| CY1121928T1 (el) | Φαρμακευτικη συνθεση υδροχλωρικης s-κεταμινης | |
| CL2023001911A1 (es) | Derivado de glucagón y una composición que comprende un conjugado de acción prolongada del mismo | |
| MX373247B (es) | Nuevos derivados de octahidro-pirrolo[3,4-c]-pirrol y análogos del mismo como inhibidores de atotaxina. | |
| CU24309B1 (es) | Compuestos derivados tienopirimidina y composiciones farmacéuticas que los contienen | |
| CY1119585T1 (el) | Ενωσεις τετραϋδροπυρρολοθειαζινης | |
| CL2017001533A1 (es) | Derivados heterocíclicos con sustituyentes que contienen azufre activos como plaguicidas | |
| ECSP17016797A (es) | Indazoles sustituidos con benzilo como inhibidores de bub1 | |
| EA201691194A1 (ru) | Стимуляторы ргц | |
| JOP20140114B1 (ar) | مركبات حلقية غير متجانسة واستخداماتها | |
| PH12016500739B1 (en) | Inhibitors of the fibrolast growth factor receptor | |
| EA201591632A1 (ru) | Цитотоксические и антимитотические соединения и способы их применения | |
| UA116467C2 (uk) | Модулятори p2x7 | |
| MX2016006815A (es) | Derivados de aminopiridina como inhibidores de cinasas de la familia de tyro3, axl y mer (tam). | |
| EA201690473A1 (ru) | Комбинированный состав двух противовирусных соединений | |
| HUE054379T2 (hu) | Helyettesített indolin-származékok mint a dengue vírus szaporodásának inhibitorai | |
| EA201500801A1 (ru) | Бензохинолоновые ингибиторы vmat2 | |
| MX2021005052A (es) | Oxiesteroles y métodos de uso de los mismos. | |
| CR20150440A (es) | Nuevos derivados de piridina | |
| CY1122822T1 (el) | Σακχαριτες παραγωγοποιημενοι με κυκλοαλκινιο | |
| MX373309B (es) | Composiciones antibióticas de ceftolozano. | |
| EA201691982A1 (ru) | 5,6-дизамещенные пиридин-2-карбоксамиды в качестве агонистов каннабиноидных рецепторов | |
| CY1120759T1 (el) | Παρασκευη διγλυκοζιτη (s,s)-σεκοϊσολαρικιρεσινολης και διγλυκοζιτη (r,r)-σεκοϊσολαρικιρεσινολης | |
| MX376414B (es) | Derivados de fenilo como agonistas del receptor de canabinoides 2. | |
| UY35997A (es) | Derivados de isoquinoleína, su procedimiento de preparación y las composiciones farmacéuticas que los contienen |